Due, C.;                     Quinn, J.;                     Gissen, P.;                     Schulz, A.;                     Specchio, N.;                     de los Reyes, E.;                     Butt, T.    
        Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa. Healthcare 2024, 12, 2229.
    https://doi.org/10.3390/healthcare12222229
    AMA Style
    
                                Due C,                                 Quinn J,                                 Gissen P,                                 Schulz A,                                 Specchio N,                                 de los Reyes E,                                 Butt T.        
                Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa. Healthcare. 2024; 12(22):2229.
        https://doi.org/10.3390/healthcare12222229
    
    Chicago/Turabian Style
    
                                Due, Christina,                                 Jennifer Quinn,                                 Paul Gissen,                                 Angela Schulz,                                 Nicola Specchio,                                 Emily de los Reyes,                                 and Thomas Butt.        
                2024. "Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa" Healthcare 12, no. 22: 2229.
        https://doi.org/10.3390/healthcare12222229
    
    APA Style
    
                                Due, C.,                                 Quinn, J.,                                 Gissen, P.,                                 Schulz, A.,                                 Specchio, N.,                                 de los Reyes, E.,                                 & Butt, T.        
        
        (2024). Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa. Healthcare, 12(22), 2229.
        https://doi.org/10.3390/healthcare12222229